Category: Alzheimer’s Disease

Unveiling the Future: A Breakthrough Blood Test for Early Alzheimer’s Detection

Introduction In the ever-evolving landscape of medical advancements, a groundbreaking study conducted by Resonant, a Utah-based biotech company specializing in diagnostic tests for neurodegenerative diseases, is developing an Alzheimer’s blood test, a potential game-changer in the early detection of Alzheimer’s disease. The research suggests that a simple blood test could be the key to identifying

Injected Version of Eisai/Biogen Alzheimer’s Drug Works as Well as IV Leqembi

On 26 October 2023, Eisai and Biogen’s Alzheimer’s drug, Leqembi, was found to be as effective as the current intravenous administration in removing toxic brain plaques. However, the review conducted by the drugmakers revealed that the rates of serious side effects were higher when using the drug in its subcutaneous injection form. The company’s analysis

SARM1 Inhibitor: A Solution Against Neurodegenerative Disorders

Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitor as potential therapeutic agent for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide. Given the encouraging research outcomes, the players in the SARM1 inhibitor market have received more than USD 10 million in grants, since 2014, from

Alzheimers Treatment and Its Evolving Market

Alzheimer’s disease is a progressive neurological disorder characterized by the death of brain cells, eventually leading to memory loss, cognitive dysfunction and dementia. Accounting for 60-70% cases of dementia, Alzheimer’s disease is known to be the sixth leading cause of death in the US.   Presently, more than 6 million Americans of all ages are living

Alzheimers Market: Developer Landscape and Competitive Insights

It was estimated that, in 2018, nearly 5.7 million Americans (considering all age groups) were living with Alzheimers. During the same year, Alzheimer’s pipeline and other dementias were projected to be responsible for a healthcare burden amounting to USD 277 billion, in the US. Despite extensive research aimed at comprehending the etiopathogenesis of Alzheimers, only